New: Introducing the Finviz Crypto Map

Ultragenyx Pharmaceutical Inc.

Contributing Author

Recent Articles by Ultragenyx Pharmaceutical Inc.

Aug-05	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Jul-31	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome RARE GlobeNewswire
Jul-30	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Jul-18	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jul-14	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) RARE GlobeNewswire
Jul-11	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) RARE GlobeNewswire
Jul-09	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis RARE GlobeNewswire
Jun-27	Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome RARE GlobeNewswire
Jun-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jun-03	Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference RARE GlobeNewswire
May-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
May-14	Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report RARE GlobeNewswire
May-07	Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference RARE GlobeNewswire
May-06	Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.